Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.
Zongru LiXiaoshuai ZhangYijing ZhaoLinping LuYong GuoRobert Peter GaleYazhen QinQian JiangPublished in: Cancer (2024)
maintenance. The results of ddPCR may identify people who benefit from imatinib dose reduction.
Keyphrases